Vulcan Value Partners LLC Lowers Stock Holdings in Medpace Holdings, Inc. $MEDP

Posted by Geri Gentry on Sep 8th, 2026

Vulcan Value Partners LLC reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 30.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 141,743 shares of the company’s stock after selling 61,325 shares during the quarter. Medpace comprises approximately 2.3% of Vulcan Value Partners LLC’s holdings, making the stock its 12th largest position. Vulcan Value Partners LLC owned 0.51% of Medpace worth $75,066,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. American Capital Management Inc. bought a new position in shares of Medpace during the second quarter valued at $111,329,000. California State Teachers Retirement System raised its position in shares of Medpace by 22.1% in the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after purchasing an additional 4,719 shares during the last quarter. BlackRock Inc. bought a new position in Medpace in the 2nd quarter worth about $1,323,047,000. Focus Partners Advisor Solutions LLC bought a new position in Medpace in the 2nd quarter worth about $1,685,000. Finally, Rice Hall James & Associates LLC purchased a new stake in Medpace during the 2nd quarter valued at about $28,659,000. Institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In related news, VP Susan Burwig sold 7,500 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the transaction, the vice president owned 62,984 shares in the company, valued at $37,790,400. This represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Fred Davenport, Jr. sold 7,283 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the sale, the director owned 3,798 shares of the company’s stock, valued at approximately $2,302,157.70. This represents a 65.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 134,471 shares of company stock valued at $82,151,311 over the last ninety days. Company insiders own 20.50% of the company’s stock.

Medpace Price Performance

NASDAQ MEDP traded down $0.40 during trading hours on Tuesday, hitting $590.89. The company’s stock had a trading volume of 185,216 shares, compared to its average volume of 338,222. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The company’s 50 day simple moving average is $575.80 and its two-hundred day simple moving average is $501.17. The company has a market cap of $16.49 billion, a P/E ratio of 34.64, a price-to-earnings-growth ratio of 2.64 and a beta of 1.15.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and increased their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Robert W. Baird raised their price target on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Finally, Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $595.20.

View Our Latest Analysis on Medpace

Medpace Company Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.